Subjective effects of MDMA ('Ecstasy') on human sexual function

Recreational use of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy') increased markedly in the decade prior to this study, with use reported in psychotherapy, small social gatherings and large all-night dance events ('raves'). Short-term psychological and sympathomimetic physical effects of MDMA last about 3–6 hours, and many users describe heightened interpersonal closeness and increased sexual arousal. Despite widespread anecdotal claims that MDMA is a "love drug", the specific effects of MDMA on discrete stages of human sexual function had not been systematically examined. Zemishlany and colleagues set out to assess how MDMA affects four major domains of sexual activity—desire, erection (lubrication in women), orgasm and satisfaction—in healthy recreational users. The study was motivated in part by MDMA’s pharmacology: it promotes release and inhibits reuptake of monoamines, especially serotonin and dopamine, neurotransmitters previously implicated in facilitation (dopamine) and inhibition (serotonin) of aspects of sexual function. The investigators therefore aimed to characterise subjective changes across the sexual cycle in people who used MDMA in sexual settings.

The investigators recruited 35 recreational MDMA users who had previously used MDMA in a sexual context: 20 men and 15 women. Inclusion required physical health, absence of major psychiatric disorder or history of sexual disorders, no alcohol or opiate abuse and no current medication. Nine participants (25%) were interviewed by telephone; the same exclusion criteria were applied in those calls. Most participants had completed secondary or higher education and were either students or employed in professional occupations. A structured interview was used to assess sexual function up to 6 hours after MDMA consumption. Four domains were evaluated: desire, erection (or vaginal lubrication in women), orgasm and satisfaction. Orgasm was further characterised by intensity and ease of achievement (premature, unchanged or delayed). Each item was rated retrospectively by the participant relative to their usual (non‑MDMA) function on a numeric scale from -3 to +3 (0 = unchanged; -1/+1 = mild change; -2/+2 = moderate change; -3/+3 = profound change). Participants reported whether they had used other substances adjunctively; the investigators noted concurrent marijuana use but restricted the primary ratings to episodes involving MDMA alone. The extracted text does not report formal dosing, laboratory confirmation of MDMA content, or a standardised laboratory setting; ratings therefore represent retrospective self‑perception of sexual function following recreational MDMA use.

All 35 participants reported increased sexual desire after MDMA use. Nineteen of 20 men (95%) and all 15 women reported increases that were moderate to profound. Most subjects described the sexual experience as more sensual than usual. Subjective satisfaction was also increased: 90% of the males and 93% of the females reported a moderate to profound increase in satisfaction. Responses for genital arousal differed by sex: among men the effect on erection was mixed, with 40% reporting an impairment and 40% reporting enhancement, while 80% of women reported increased vaginal lubrication. MDMA was commonly associated with delayed orgasm. Sixteen men (80%) and six women (40%) described delayed achievement of orgasm; one man and two women reported complete inability to achieve orgasm (anorgasmia) on the drug. Despite delays, orgasm was perceived as more intense by 85% of men and 53% of women. Concurrent marijuana use was reported by ten males (50%) and ten females (67%), equivalent to 20 of 35 participants (57%). Those who used marijuana as an adjunct reported that it tended to increase sexual desire, but the study’s ratings were restricted to MDMA alone and the investigators reported no differences in the measured sexual parameters between concomitant marijuana users and non‑users in this sample. The detailed tabulated data referenced in the paper (table I) is not reproduced in the extracted text.

Zemishlany and colleagues interpreted their findings as indicating that MDMA enhances subjective sexual desire, overall satisfaction, female arousal and orgasmic intensity, while simultaneously prolonging orgasm latency and producing inconsistent effects on male erectile function. The authors noted that roughly 40% of men reported decreased erectile ability—an observation consistent with at least one previous survey in a different population which likewise found increased sensuality, more difficult orgasm and reduced erection in a substantial subset of men. The investigators related their results to prevailing neurobiological hypotheses: increased dopaminergic activity is thought to facilitate sexual desire and possibly erectile responses, whereas increased serotonergic activity is associated with inhibition of erection and orgasm. MDMA’s ability to release both dopamine and serotonin could therefore plausibly account for the mixed pattern observed—heightened desire and satisfaction alongside delayed orgasm and some erectile dysfunction. The authors also suggested that peripheral sympathomimetic effects of MDMA might contribute to erectile problems. They acknowledged the potential influence of expectancy or placebo effects, noting analogue evidence that substances such as alcohol can produce self‑reported increases in sexual arousal despite objective decreases in reactivity. Several methodological limitations were emphasised: the non‑random, self‑selecting sample of people willing to discuss illegal drug use; reliance on retrospective self‑report; lack of information on MDMA dose and pill purity; and the frequent concomitant use of marijuana, which may confound attribution of effects. Despite these caveats, the authors concluded that in sexual settings MDMA appears to boost subjective desire and satisfaction while often impairing aspects of sexual performance, notably orgasm timing and, for some men, erectile ability.